AMBISOME by Astellas is clinical pharmacology pharmacokinetics the assay used to measure amphotericin b in the serum after administration of am b isome does not distinguish amphotericin b that is complexed with the phospholipids of am b isome from amphotericin b that is uncomplexed. First approved in 1997.
Drug data last refreshed 12h ago · AI intelligence enriched 1mo ago
AMBISOME is a liposomal formulation of amphotericin B, a lipid-based polyene antifungal agent used to treat serious systemic fungal infections. The drug works by binding to fungal cell membrane ergosterol, disrupting membrane integrity and causing cell death. It is indicated for patients with invasive fungal infections who cannot tolerate or have failed conventional amphotericin B therapy.
LOE approaching signals a contracting team; roles focus on maintaining market share and managing transition planning rather than growth initiatives.
CLINICAL PHARMACOLOGY Pharmacokinetics The assay used to measure amphotericin B in the serum after administration of Am B isome does not distinguish amphotericin B that is complexed with the phospholipids of Am B isome from amphotericin B that is uncomplexed. The pharmacokinetic profile of…
Worked on AMBISOME at Astellas? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trial to Assess the Safety and Efficacy of Sodium Stibogluconate (SSG) and AmBisome® Combination, Miltefosine and AmBisome® and Miltefosine Alone for the Treatment Visceral Leishmaniasis in Eastern Africa
Ambisome® Preemptive Treatment of Multiple Candida Colonization in Sepsis Patients
The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) Study
Ambisome and Management of Culture-negative Neutropenic Fever Unresponsive to Antibiotics
PROPHESSOR: AmBisome in Antifungal Primary Prophylaxis Treatment of High Risk Patients Undergoing Allogeneic Stem Cell Transplantation
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moAMBISOME offers limited career growth due to its LOE-approaching lifecycle and declining linked job postings (0 identified). Working on this product means focusing on market defense, payer negotiations, and operational efficiency rather than launch excitement or commercial expansion.